Who we are
A not-for-profit research organization developing new treatments for neglected patients
Born on the frontlines of medical action
Millions of people around the world die every year from lack of treatment. Yet only a fraction of the world’s pharmaceutical research and development focuses on diseases affecting poor and vulnerable communities.
When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, they dedicated a portion of the award to addressing this fatal imbalance and exploring a new, alternative, not-for-profit model for developing drugs for neglected patients.
In 2003, MSF, the World Health Organization, and five international research institutions founded the Drugs for Neglected Diseases initiative (DNDi).
We discover, develop, and deliver new treatments for neglected patients around the world that are affordable and patient-friendly – and have already saved millions of lives.
‘When we received the Nobel Peace Prize in 1999, MSF did not have the medicines we needed to carry out our lifesaving work. So we decided to dedicate a portion of the funds received to launch a brand-new model of R&D. Four years later, DNDi was born.’
Dr Bernard Pécoul, Former MSF France General Director, now DNDi Executive Director
In 2003, DNDi’s seven founding partners came together to respond to the frustration of doctors and health workers around the world faced with medicines that were ineffective, unsafe, unavailable, unaffordable – or that had never been developed at all.
Get our latest news, personal stories, research articles, and job opportunities.